Alteration of DSS-mediated immune cell redistribution in murine colitis by oral colostral immunoglobulin

BMC Immunology

Claus Kerkhoff³  Claudia Maletzki⁴  Sebastian Klammt²  Elisabeth Zirzow¹  Peggy Bodammer³ 

[1] Division of Gastroenterology, Department of Medicine II, University of Rostock, Rostock 18057, Germany;Centre for Coordination of Clinical studies, University of Rostock, Rostock, 18057, Germany;Department of Immunology, Project group “Extracorporal Immunomodulation”, Fraunhofer Institute for Cell Therapy and Immunology, Rostock 18057, Germany;Department of General, Vascular, Thoracic and Transplantation Surgery, Section of Molecular Oncology and Immunotherapy, University of Rostock, Rostock, 18057, Germany

关键词: Outbred NMRI mice;    Myeloid-derived suppressor cells;    γδ- T-cells;    Bovine lactoferrin;    Secretory immunoglobulin A;    Colostrum;    Recovery;    DSS-colitis;   

Others  :  1077835
DOI  :  10.1186/1471-2172-14-10

 received in 2012-09-06, accepted in 2013-02-01,  发布年份 2013

【 摘 要 】

Background

Oral bovine colostrum prophylaxis accelerates the recovery of dextran sulfate sodium (DSS)-induced colitis. In the present study the beneficial effects on acute intestinal inflammation of two major colostral components, secretory immunoglobulin A and lactoferrin, were investigated. Outbred NMRI mice received whole bovine colostrum (BC, 20 mg/kg body weight), colostral bovine lactoferrin (bLf, 150 mg/kg), or secretory immunoglobulin A (sIgA, 1–2 mg/kg body weight) daily by oral gavage, either two weeks before induction of colitis (prophylaxis) or after disease establishment (therapy). Bovine serum albumin (BSA, 150 mg/kg body weight) and immunoglobulin G (IgG, 1 and 2 mg/kg body weight) served as protein controls. Colitis was induced by providing 5% DSS solution ad libitum for seven days.

Results

Compared to BSA, BC therapy improved occult blood, stool consistency, and clinical recovery from colitis but did not prevent initial weight loss. In contrast, administration of bLf did not influence the course of colitis in either the prophylactic or the therapeutic setting. Therapeutic application of sIgA promoted weight gain in the recovery phase of colitis but failed to improve other clinical parameters. Prophylactically-fed sIgA influenced immune cell redistribution, normalized peripheral blood CD11c⁺CD83⁺ mature dendritic cells, modulated colonic immune cell infiltration, and altered the numbers of both DSS-induced regulatory γδ TCR⁺ T cells and CD11b⁺Gr-1⁺ myeloid suppressor cells in the lymph nodes and spleens of mice.

Conclusions

These data demonstrated the potential of colostrum in disease recovery and epithelial homeostasis following intestinal injury. Colostral sIgA failed to improve acute disease activity but promoted weight gain and modulated immune cell responses that are involved in the genesis of colitis.

【 授权许可】

   
2013 Bodammer et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Triantafillidis JK, Merikas E, Georgopoulos F: Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther 2011, 5:185-210.
• [2]Langmead L, Rampton DS: Review article: complementary and alternative therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2006, 23:341-349.
• [3]Playford RJ, Macdonald CE, Johnson WS: Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders. Am J Clin Nutr 2000, 72:5-14.
• [4]Solomons NW: Modulation of the immune system and the response against pathogens with bovine colostrum concentrates. Eur J Clin Nutr 2002, 56(Suppl 3):24-28.
• [5]Bodammer P, Maletzki C, Waitz G, Emmrich J: Prophylactic application of bovine colostrum ameliorates murine colitis via induction of immunoregulatory cells. J Nutr 2011, 141:1056-1061.
• [6]Brandtzaeg P, Carlsen HS, Halstensen TS: The B-cell system in inflammatory bowel disease. Adv Exp Med Biol 2006, 579:149-167.
• [7]Thoree VC, Golby SJ, Boursier L, Hackett M, Dunn-Walters DK, Sanderson JD, Spencer J: Related IgA1 and IgG producing cells in blood and diseased mucosa in ulcerative colitis. Gut 2002, 51:44-50.
• [8]Murthy AK, Dubose CN, Banas JA, Coalson JJ, Arulanandam BP: Contribution of polymeric immunoglobulin receptor to regulation of intestinal inflammation in dextran sulfate sodium-induced colitis. J Gastroenterol Hepatol 2006, 21:1372-1380.
• [9]Carbonare CB, Carbonare SB, Carneiro-Sampaio MM: Secretory immunoglobulin a obtained from pooled human colostrum and milk for oral passive immunization. Pediatr Allergy Immunol 2005, 16:574-581.
• [10]Sawai T, Goldstone N, Drongowski RA, Coran AG, Harmon CM: Effect of secretory immunoglobulin a on bacterial translocation in an enterocyte-lymphocyte co-culture model. Pediatr Surg Int 2001, 17:275-279.
• [11]Actor JK, Hwang SA, Kruzel ML: Lactoferrin as a natural immune modulator. Curr Pharm Des 2009, 15:1956-1973.
• [12]Buccigrossi V, de Marco G, Bruzzese E, Ombrato L, Bracale I, Polito G, Guarino A: Lactoferrin induces concentration-dependent functional modulation of intestinal proliferation and differentiation. Pediatr Res 2007, 61:410-414.
• [13]Debbabi H, Dubarry M, Rautureau M, Tomé D: Bovine lactoferrin induces both mucosal and systemic immune response in mice. J Dairy Res 1998, 65:283-293.
• [14]Sfeir RM, Dubarry M, Boyaka PN, Rautureau M, Tomé D: The mode of oral bovine lactoferrin administration influences mucosal and systemic immune responses in mice. J Nutr 2004, 134:403-409.
• [15]Håversen LA, Baltzer L, Dolphin G, Hanson LA, Mattsby-Baltzer I: Anti-inflammatory activities of human lactoferrin in acute dextran sulphate-induced colitis in mice. Scand J Immunol 2003, 57:2-10.
• [16]Togawa J, Nagase H, Tanaka K, Inamori M, Nakajima A, Ueno N, Saito T, Sekihara H: Oral administration of lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. J Gastroenterol Hepatol 2002, 17:1291.
• [17]Zhang R, Ito S, Nishio N, Cheng Z, Suzuki H, Isobe KI: Dextran sulphate sodium increases splenic Gr1(+)CD11b(+) cells which accelerate recovery from colitis following intravenous transplantation. Clin Exp Immunol 2011, 164:417-427.
• [18]Fischer R, Debbabi H, Blais A, Dubarry M, Rautureau M, Boyaka PN, Tome D: Uptake of ingested bovine lactoferrin and its accumulation in adult mouse tissues. Int Immunopharmacol 2007, 10:1387-1393.
• [19]Warny M, Fatimi A, Bostwick EF, Laine DC, Lebel F, LaMont JT, Pothoulakis C, Kelly CP: Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut 1999, 44:212-217.
• [20]Hirotani Y, Ikeda K, Kato R, Myotoku M, Umeda T, Ijiri Y, Tanaka K: Protective effects of lactoferrin against intestinal mucosal damage induced by lipopolysaccharide in human intestinal caco-2 cells. Yakugaku Zasshi 2008, 128:1363-1368.
• [21]Tsuchiya T, Fukuda S, Hamada H, Nakamura A, Kohama Y, Ishikawa H, Tsujikawa K, Yamamoto H: Role of gamma delta T cells in the inflammatory response of experimental colitis mice. J Immunol 2003, 171:5507-5513.
• [22]Giacomelli R, Parzanese I, Frieri G, Passacantando A, Pizzuto F, Pimpo T, Cipriani P, Viscido A, Caprilli R, Tonietti G: Increase of circulating gamma/delta T lymphocytes in the peripheral blood of patients affected by active inflammatory bowel disease. Clin Exp Immunol 1994, 98:83-88.
• [23]Kühl AA, Pawlowski NN, Grollich K, Blessenohl M, Westermann J, Zeitz M, Loddenkemper C, Hoffmann JC: Human peripheral gammadelta T cells possess regulatory potential. Immunology 2009, 128:580-588.
• [24]Boismenu R, Havran WL: Modulation of epithelial cell growth by intraepithelial gamma delta T cells. Science 1994, 266:1253-1255.
• [25]Komano H, Fujiura Y, Kawaguchi M, Matsumoto S, Hashimoto Y, Obana S, Mombaerts P, Tonegawa S, Yamamoto H, Itohara S, Nannot M, Ishikawat H: Homeostatic regulation of intestinal epithelia by intraepithelial gamma delta T cells. Proc Natl Acad Sci 1995, 92:6147-6151.
• [26]Kühl AA, Loddenkemper C, Westermann J, Hoffmann JC: Role of gamma delta T cells in inflammatory bowel disease. Pathobiology 2002–2003, 70:150-155.
• [27]Kühl AA, Pawlowski NN, Grollich K, Loddenkemper C, Zeitz M, Hoffmann JC: Aggravation of intestinal inflammation by depletion/deficiency of gammadelta T cells in different types of IBD animal models. J Leukoc Biol 2007, 81:168-175.
• [28]Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98:694-702.
• [29]Cooper HS, Murthy SN, Shah RS, Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993, 69:238-249.
• [30]Brunner E, Domhof S, Langer F: Nonparametric analysis of longitudinal data in factorial experiments. In Probability and Statistics. New York: John Wiley & Sons; 2002.
• [31]Mann HB, Whitney DR: On a test of whether one of Two random variables is stochastically larger than the other. Annals Math Stats 1947, 18:50-60.